Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2022

May 13, 2022

SELL
$17.46 - $26.36 $40.3 Million - $60.9 Million
-2,309,554 Closed
0 $0
Q2 2020

Aug 04, 2020

BUY
$26.15 - $35.45 $60.4 Million - $81.9 Million
2,309,554 New
2,309,554 $73 Million

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.1B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Frazier Management LLC Portfolio

Follow Frazier Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Frazier Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Frazier Management LLC with notifications on news.